Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis
Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A
International journal of cardiology · 199 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Australian Government
Según 1 financiador declarado.
Publicación
- Publicado
- 2008-09-07 · Int J Cardiol · vol. 136 · número 1 · págs. 4–16
- Editorial
- Elsevier BV
- Citado
- 298 citas · más que el 79% de estudios similares · 1.2× el promedio de su campo
- Referencias
- 87 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Aquaculture Nutrition and Growth
- Palabras clave
- fish oil supplementation, hyperlipidemia, triglycerides, EPA, docosahexaenoic acid, HDL cholesterol, LDL cholesterol, total cholesterol, serum lipids, dose-response relationship
- MeSH
- animals, humans, dietary fats, triglycerides, fish oils, dietary supplements, cholesterol, ldl, hyperlipidemias, cholesterol, hdl, randomized controlled trials as topic
5 autores
- Guy D. Eslick🇦🇺Western Sydney University
- Peter R.C. Howe🇦🇺University of South Australia
- Caroline Anne Smith🇦🇺Western Sydney University
- Ros Priest🇦🇺Western Sydney University
- Alan Bensoussan🇦🇺Western Sydney University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Fish oils have been widely reported as a useful supplement to reduce fasting blood triglyceride levels in individuals with hyperlipidemia. We performed an updated meta-analysis to quantitatively evaluate all the randomized trials of fish oils in hyperlipidemic subjects.
Methods
We conducted a systematic literature search using several electronic databases supplemented by manual searches of published reference lists, review articles and conference abstracts. We included all placebo-controlled randomized trials of parallel design that evaluated any of the main blood lipid outcomes: total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol or triglycerides (TG). Data were pooled using DerSimonian-Laird's random effects model.
Results
The final analysis comprised of 47 studies in otherwise untreated subjects showed that taking fish oils (weighted average daily intake of 3.25 g of EPA and/or DHA) produced a clinically significant reduction of TG (-0.34 mmol/L, 95% CI: -0.41 to -0.27), no change in total cholesterol (-0.01 mmol/L, 95% CI: -0.03 to 0.01) and very slight increases in HDL (0.01 mmol/L, 95% CI: 0.00 to 0.02) and LDL cholesterol (0.06 mmol/L, 95% CI: 0.03 to 0.09). The reduction of TG correlated with both EPA+DHA intake and initial TG level.
Conclusion
Fish oil supplementation produces a clinically significant dose-dependent reduction of fasting blood TG but not total, HDL or LDL cholesterol in hyperlipidemic subjects.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.